Urine nevirapine as a predictor of antiretroviral adherence

Indian Journal of Medical Research

Volumn 123, Issue 4, 2006, Pages 565-568

  Hemanth Kumar, A K ^a   Ramachandran, Geetha ^a   Saradha, Banu ^a   Narendran, G ^a   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

Antiretroviral adherence; HIV; Predictor; Urine nevirapine

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; FEASIBILITY STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; PREDICTION; SEX DIFFERENCE; SINGLE DRUG DOSE; TIME; TREATMENT OUTCOME; URINALYSIS; URINARY EXCRETION; VOLUNTEER;

ADULT; ANTI-HIV AGENTS; DRUG MONITORING; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; PATIENT COMPLIANCE;

EID: 33745460298     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338 : 853-60.
2. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353 : 863-8.
3. Fletcher CV. Pharmacologic considerations for therapeutic success with antiretroviral agents. Ann Pharmacother 1999; 33 : 989-95.
4. Bangsberg DR, Perry S, Charlebois ED, Clarke RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15 : 181-3.
5. Hogg RS, Heath K, Bangsberg D, Yip D, Press N, O'shaughnessy MV, et al. Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year off follow-up. AIDS 2002; 16 : 1051-8.
6. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134 : 968-77.
7. Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider accuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS 2002; 16 : 1835-7.
8. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999; 27 : 895-901.
9. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterisation of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27: 1488-95.
10. Phair JP, Becker SL. Integrating pharmacokinetics into treatment decisions: Strategies for optimal patient care. iMed Options Northwestern University, Feinberg School of Medicine, Office of Continuing Medical Education, USA; 2004.
11. Murphy D, Roberts K, Marelich W, Hoffman D. Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care 2000; 14 : 47-58.
12. Kastrissios H, Suarez JR, Hammer S, Katzenstein D, Blaschke TF, et al. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. AIDS 1998; 12 : 2305-11.
13. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Cheng CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33 : 1417-23.
14. Hugen PW, Langebeek N, Burger DM, Zomer B, van Leusen R, Schuurman R, et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods including MEMS (electronic monitoring), patient and nurse report and therapeutic drug monitoring. J Acquir Immune Defic Syndr 2002; 30: 324-34.
15. van Rossum. AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21 : 743-7.
16. Venkataraman P, Eidus L, Ramachandran K, Tripathy SP. A comparison of various methods for the detection of isoniazid and its metabolites in urine. Tubercle 1965; 46 : 262-9.